Rozemarijn S van Rijn Selected Research

Rituximab (Mabthera)

1/2018	Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach.
7/2006	Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rozemarijn S van Rijn Research Topics

Disease

25	Melanoma (Melanoma, Malignant) 01/2024 - 01/2017
7	Neoplasms (Cancer) 01/2023 - 07/2006
5	Neoplasm Metastasis (Metastasis) 01/2024 - 06/2018
5	Brain Neoplasms (Brain Tumor) 05/2023 - 01/2018
2	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2007 - 09/2006
1	Death (Near-Death Experience) 10/2022
1	Hepatitis 04/2021
1	Immune System Diseases (Immune Disorders) 01/2021
1	Autoimmune Diseases (Autoimmune Disease) 01/2021
1	Necrosis 06/2018
1	B-Cell Lymphoma (Lymphoma, B Cell) 06/2018
1	Hodgkin Disease (Hodgkin's Disease) 06/2018
1	Colitis 01/2018
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2018
1	Leukemia 09/2006
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 07/2006

Drug/Important Bio-Agent (IBA)

11	Immune Checkpoint InhibitorsIBA 01/2024 - 12/2019
9	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2024 - 01/2018
7	IpilimumabIBA 01/2023 - 01/2018
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2024 - 12/2022
3	NivolumabIBA 01/2023 - 09/2022
2	Rituximab (Mabthera)FDA Link 01/2018 - 07/2006
1	A-factor (Streptomyces)IBA 09/2022
1	antineoplaston A10 (A 10)IBA 09/2021
1	Programmed Cell Death 1 ReceptorIBA 04/2021
1	Lactate DehydrogenasesIBA 11/2020
1	SteroidsIBA 01/2020
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 06/2018
1	VemurafenibIBA 01/2018
1	Monoclonal AntibodiesIBA 01/2018
1	Proteins (Proteins, Gene)FDA Link 01/2017
1	Phosphotransferases (Kinase)IBA 01/2017
1	MitogensIBA 01/2017
1	AntigensIBA 01/2007
1	AntibodiesIBA 07/2006

Therapy/Procedure

16	Therapeutics 01/2024 - 01/2018
1	Duration of Therapy 01/2022
1	Immunotherapy 05/2020
1	Drug Therapy (Chemotherapy) 01/2018
1	Stem Cell Transplantation 09/2006